BioStem Technologies Appoints Katherine Gorrell as Chief Legal & Compliance Officer Amid Nasdaq Uplisting Push

BioStem Technologies (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced Wednesday the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. The move comes as the company prepares for a potential Nasdaq uplisting and seeks to strengthen its governance framework amid rapid growth.

Gorrell brings over two decades of experience advising hospital systems and health technology companies on complex regulatory, transactional, and compliance matters. In her new role, she will oversee BioStem’s legal and compliance functions and play a central role in enterprise governance, including integrating Medical Affairs into the company’s compliance framework.

“Katherine is a key addition to BioStem as we implement our next phase of growth,” said Jason Matuszewski, Chairman and CEO of BioStem Technologies, in a press release. “Her leadership will support our continued scaling while reinforcing our strong foundation of integrity and compliance, especially as we progress toward a Nasdaq uplisting.”

Most recently, Gorrell served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, Florida, where she was a member of the executive team and led legal strategy across a complex healthcare enterprise. Previously, she was General Counsel and Compliance Officer for AdvancedMD, a national healthcare IT company, and held in-house roles at Intermountain Healthcare and Providence Health & Services/Swedish Health Services.

Gorrell holds a JD with Honors, with a concentration in Health Law, from the University of Washington School of Law, and a Bachelor of Arts with Honors in Political Science from the University of Utah.

“BioStem is at a pivotal time in its growth and evolution. I look forward to working with the leadership team and board to support sustainable growth, strengthen governance, and ensure our legal, compliance, and medical affairs functions continue to evolve with the business,” Gorrell said.

BioStem Technologies develops and manufactures advanced allograft solutions derived from perinatal tissue, using proprietary processing technologies such as BioRetain, CryoTek, and SteriTek. The company’s products are used across a wide range of clinical specialties. BioStem’s quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices and current Good Manufacturing Processes.

The appointment signals BioStem’s commitment to scaling its operations while maintaining rigorous compliance standards—a critical factor for companies pursuing uplisting to a major exchange. The company’s latest news and updates are available in the company’s newsroom at https://tinyurl.com/bsemnewsroom.

This news story relied on content distributed by PRISM Mediawire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is BioStem Technologies Appoints Katherine Gorrell as Chief Legal & Compliance Officer Amid Nasdaq Uplisting Push.

The post BioStem Technologies Appoints Katherine Gorrell as Chief Legal & Compliance Officer Amid Nasdaq Uplisting Push appeared first on citybuzz.